19.96
Overview
News
Price History
Option Chain
Financials
Why TEVA Down?
Discussions
Forecast
Stock Split
Dividend History
Teva Pharmaceutical Industries Ltd Adr stock is traded at $19.96, with a volume of 9.33M.
It is down -0.25% in the last 24 hours and up +5.33% over the past month.
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$20.01
Open:
$20.02
24h Volume:
9.33M
Relative Volume:
0.84
Market Cap:
$22.89B
Revenue:
$16.70B
Net Income/Loss:
$-157.13M
P/E Ratio:
-138.04
EPS:
-0.1446
Net Cash Flow:
$1.19B
1W Performance:
+4.07%
1M Performance:
+5.33%
6M Performance:
+44.64%
1Y Performance:
+14.12%
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Name
Teva Pharmaceutical Industries Ltd Adr
Sector
Phone
972 (3) 914-8213
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.96 | 22.95B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
ZTS
Zoetis Inc
|
145.36 | 64.89B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.11B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
8.79 | 39.85B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
UTHR
United Therapeutics Corp
|
453.28 | 20.49B | 3.08B | 1.24B | 1.07B | 25.61 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-06-25 | Initiated | Goldman | Buy |
May-28-25 | Initiated | Truist | Buy |
May-12-25 | Upgrade | JP Morgan | Neutral → Overweight |
Jul-10-24 | Upgrade | Argus | Hold → Buy |
Mar-08-24 | Upgrade | JP Morgan | Underweight → Neutral |
Feb-12-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-23-24 | Upgrade | Jefferies | Hold → Buy |
Jan-03-24 | Upgrade | Piper Sandler | Underweight → Neutral |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Nov-27-23 | Upgrade | UBS | Neutral → Buy |
Jul-06-23 | Upgrade | UBS | Sell → Neutral |
May-25-23 | Initiated | Morgan Stanley | Equal-Weight |
May-18-23 | Upgrade | Evercore ISI | In-line → Outperform |
Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
Nov-14-22 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-04-22 | Downgrade | UBS | Neutral → Sell |
Oct-21-22 | Resumed | Jefferies | Buy |
Aug-05-22 | Upgrade | BofA Securities | Neutral → Buy |
Jun-14-22 | Resumed | UBS | Neutral |
May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
May-04-22 | Downgrade | Piper Sandler | Neutral → Underweight |
Apr-05-22 | Upgrade | Barclays | Equal Weight → Overweight |
Mar-25-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Jan-27-22 | Downgrade | Argus | Buy → Hold |
Oct-28-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-04-21 | Downgrade | UBS | Buy → Neutral |
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Nov-25-20 | Initiated | Oppenheimer | Perform |
Aug-06-20 | Upgrade | Barclays | Underweight → Equal Weight |
Jul-27-20 | Resumed | Goldman | Neutral |
Jun-01-20 | Upgrade | SunTrust | Hold → Buy |
Apr-24-20 | Resumed | Citigroup | Neutral |
Apr-06-20 | Upgrade | UBS | Neutral → Buy |
Feb-24-20 | Downgrade | Edward Jones | Hold → Sell |
Nov-12-19 | Upgrade | JP Morgan | Underweight → Neutral |
Oct-17-19 | Upgrade | Gabelli & Co | Hold → Buy |
Aug-07-19 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-19-19 | Initiated | Wolfe Research | Peer Perform |
Jul-15-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jul-10-19 | Resumed | Credit Suisse | Neutral |
Jul-05-19 | Upgrade | Argus | Hold → Buy |
Jun-11-19 | Initiated | Barclays | Underweight |
Jun-03-19 | Upgrade | Oppenheimer | Perform → Outperform |
May-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
May-28-19 | Downgrade | UBS | Buy → Neutral |
Mar-20-19 | Initiated | SunTrust | Hold |
Mar-07-19 | Resumed | UBS | Buy |
View All
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters - The Motley Fool
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm
Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl
Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se
TEVA Stock Price and Chart — TASE:TEVA - TradingView
TEVA Stock Price and Chart — NYSE:TEVA - TradingView
Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com
Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Navigating a Year of Volatility - investchronicle.com
Teva's AJOVY Receives FDA Approval for Pediatric Migraine Treatment - AInvest
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Ariva
TEVA’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com
Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid - Morningstar
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components - Ariva
Head-To-Head Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Drops -2.31%, Turning Investors Away - Stocksregister
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?26.06.25News - Ariva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by Yousif Capital Management LLC - Defense World
Can Teva- Pharmaceutical Industries Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Stocks Generating Improved Relative Strength: Teva Pharmaceutical ADR - MSN
Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
Teva: New Long-Term Targets and Solid Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
Teva Earnings: Innovation Propels Sales and Generics Show Stability in Solid Start to the Year - Morningstar
Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com
Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Canada
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):